PRO DEX Inc.

PDEX

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000788920

A

strongest fifth of 369 graded peers in healthcare

rank 44 of 369; percentile 11.7; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard


Profitability	C percentile 47.9
Solvency	B percentile 26.3
Growth and financing	B percentile 27.4
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $74.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	12 of 14
Graded from	filings received through Sep 3, 2026 58 days before the rescan; latest periodic filing 10-Q received Oct 29, 2026
Last close	$58.95 2026-10-30; market equity $188.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Sep 3, 2026

"Pro-Dex," "we," "our," "us") specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial ("CMF") markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality and regulatory consulting services to our customers. We also manufacture and sell rotary air motors to a wide range of industries; however, these motors comprise a de minimis portion of our business.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 47.9						
Gross profitability	32.7%	32.4%		45.5	366	2026-06-30
Return on invested capital	18.1%	9.3%		23.3	74	2026-06-30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	9.5%	(6.6%)	91.1	803	2026-06-30
Gross margin stability, five years	1.8 pts	2.8 pts	31.5	242	2026-06-30
Solvency, sleeve percentile 26.3					
Twelve-month failure probability	0.03%	0.07%	16.7	246	2026-09-30
Altman Z double-prime	8.66	(0.35)	10.7	748	2026-06-30
Net debt to EBITDA	0.65x	1.82x	33.8	75	2026-06-30
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-06-30; latest annual assets end 2026-06-30					
Current ratio	4.10x	2.92x	44.0	829	2026-06-30
Growth and financing, sleeve percentile 27.4					
Revenue growth, three-year compound	18.9%	10.1%	33.3	412	2026-06-30
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 12					
Reinvestment rate	67.9%	37.1%	40.8	104	2026-06-30
Asset growth, three years	12.9%	2.2%	28.3	696	2026-06-30
Net share issuance, one year	(1.8%)	2.5%	7.3	631	2026-09-02

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
39	TG Therapeutics, Inc. (TGTX)	10.3	A	
40	TransMedics Group, Inc. (TMDX)	10.6	A	
41	Niagen Bioscience, Inc. (NAGE)	10.9	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	
43	Sanara MedTech Inc. (SMTI)	11.4	A	
44	PRO DEX Inc. (PDEX)	11.7	A	
45	Idexx Laboratories Inc. (IDXX)	12.0	A	
46	Natera, Inc. (NTRA)	12.2	A	fortress balance sheet
47	Procept BioRobotics Corp. (PRCT)	12.5	A	fortress balance sheet
48	Insulet Corp. (PODD)	12.8	A	
49	Utah Medical Products Inc. (UTMD)	13.0	A	fortress balance sheet

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	83.5%	7.3%	85
Distance from 52-week high	(20.8%)	(28.7%)	61
EBIT to enterprise value	6.8%	(1.4%)	86
Free cash flow yield	3.6%	(1.0%)	73
Book value to price	0.27	0.28	48
Sales to price	0.42	0.30	61
Composite equity issuance, five years	(13.0%)	20.5%	13

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	0.39	(0.14)	85

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$11.8M
Operating cash flow, four quarters	$11.4M
Months of runway	not finite
Days since last periodic filing	2 (10-Q received Oct 29, 2026)
Median daily dollar volume, 63 sessions	$3.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$24.3M	2026-06-30	2026-09-03	10-K	26-001215
2	assets	us-gaap:Assets	$74.5M	2026-06-30	2026-09-03	10-K	26-001215
3	operating income	us-gaap:OperatingIncomeLoss	$13.0M	2026-06-30	2026-09-03	10-K	26-001215
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$18.0M	2026-06-30	2026-09-03	10-K	26-001215
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$4.4M	2026-06-30	2026-09-03	10-K	26-001215
6	total debt	us-gaap:LongTermDebt	$17.5M	2026-06-30	2026-09-03	10-K	26-001215
7	book equity	us-gaap:StockholdersEquity	$47.6M	2026-06-30	2026-09-03	10-K	26-001215
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$8.2M	2026-06-30	2026-09-03	10-K	26-001215
9	total debt	us-gaap:LongTermDebt	$15.4M	2025-06-30	2025-09-04	10-K	25-001426
10	book equity	us-gaap:StockholdersEquity	$36.6M	2025-06-30	2026-09-03	10-K	26-001215
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$419,000	2025-06-30	2026-09-03	10-K	26-001215
12	net income	us-gaap:NetIncomeLoss	$13.7M	2026-06-30	2026-09-03	10-K	26-001215
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$7.2M	2026-06-30	2026-09-03	10-K	26-001215
14	assets	us-gaap:Assets	$61.2M	2025-06-30	2026-09-03	10-K	26-001215
15	revenue	us-gaap:Revenues	$77.5M	2026-06-30	2026-09-03	10-K	26-001215
16	gross profit	us-gaap:GrossProfit	$19.5M	2025-06-30	2026-09-03	10-K	26-001215
17	revenue	us-gaap:Revenues	$66.6M	2025-06-30	2026-09-03	10-K	26-001215
18	gross profit	us-gaap:GrossProfit	$14.6M	2024-06-30	2025-09-04	10-K	25-001426
19	revenue	us-gaap:Revenues	$53.8M	2024-06-30	2025-09-04	10-K	25-001426
20	gross profit	us-gaap:GrossProfit	$12.7M	2023-06-30	2024-09-05	10-K	24-000079
21	revenue	us-gaap:Revenues	$46.1M	2023-06-30	2024-09-05	10-K	24-000079
22	gross profit	us-gaap:GrossProfit	$13.1M	2022-06-30	2023-10-13	10-K	23-001429
23	revenue	us-gaap:Revenues	$42.0M	2022-06-30	2023-10-13	10-K	23-001429
24	current assets	us-gaap:AssetsCurrent	$53.2M	2026-06-30	2026-09-03	10-K	26-001215
25	current liabilities	us-gaap:LiabilitiesCurrent	$13.0M	2026-06-30	2026-09-03	10-K	26-001215
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$47.6M	2026-06-30	2026-09-03	10-K	26-001215
27	liabilities	us-gaap:Liabilities	$26.9M	2026-06-30	2026-09-03	10-K	26-001215
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.4M	2026-06-30	2026-09-03	10-K	26-001215
29	operating income	us-gaap:OperatingIncomeLoss	$5.8M	2023-06-30	2024-09-05	10-K	24-000079
30	interest expense	us-gaap:InterestExpense	$533,000	2023-06-30	2023-10-13	10-K	23-001429

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$483,000	2026-06-30	2026-09-03	10-K	26-001215
32	current assets	us-gaap:AssetsCurrent	$47.3M	2025-06-30	2026-09-03	10-K	26-001215
33	current liabilities	us-gaap:LiabilitiesCurrent	$14.6M	2025-06-30	2026-09-03	10-K	26-001215
34	assets	us-gaap:Assets	$52.5M	2024-06-30	2025-09-04	10-K	25-001426
35	assets	us-gaap:Assets	$51.8M	2023-06-30	2024-09-05	10-K	24-000079
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,203,334	2026-09-02	2026-09-03	10-K	26-001215
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,261,979	2025-09-03	2025-09-04	10-K	25-001426

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.